Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity

Area of Science:

• Immunology
• Biomaterials Science
• Vaccine Development

Background:

• Biomaterial vaccines protect, target, and deliver signals to immune organs like lymph nodes (LNs).
• Systemic vaccine delivery complicates understanding individual component impacts on immune response.
• Intra-lymph node (i.LN.) injection allows precise study of LN environment responses to vaccine components.

Purpose of the Study:

• To investigate the impact of vaccine component doses, kinetics, and combinations on the LN environment via i.LN. injection.
• To analyze local and systemic immune responses to vaccines containing soluble antigen and adjuvant-loaded microparticles.
• To evaluate the potential of i.LN. delivery for cancer immunotherapy.

Main Methods:

• Utilized direct i.LN. injection of vaccines comprising soluble antigen and polymer microparticles with toll-like receptor agonists.
• Assessed changes in antigen-presenting cells and lymphocytes within LNs.
• Quantified antigen-specific CD8+ T cell expansion, contraction, and memory development in blood.
• Evaluated therapeutic efficacy in a metastatic melanoma model using i.LN. depot delivery.

Main Results:

• Microparticle vaccines significantly increased and activated antigen-presenting cells and lymphocytes in LNs.
• Antigen-specific CD8+ T cell responses showed expansion within 7 days and memory development over 1 month.
• i.LN. delivery of tumor antigen vaccines induced primary and recall CD8+ T cell responses.
• Local i.LN. depot delivery slowed melanoma tumor growth more effectively than a potent human vaccine adjuvant.

Conclusions:

• i.LN. injection is a powerful tool for dissecting vaccine component effects on immune responses.
• Microparticle-based vaccines delivered i.LN. enhance cellular immunity and generate antigen-specific T cell memory.
• Targeted, local i.LN. immunotherapy can elicit potent, systemic anti-tumor responses, offering a promising strategy for aggressive cancers.